Flucytosine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Systemic fungal infections
Adult: 200 mg/kg daily in 4 divided doses via infusion over 20-40 min. Adjust dose to produce trough plasma levels of 25-50 mcg/mL. In severe systemic candidiasis, cryptococcal meningitis and other severe infections, it is usually given in combination w/ amphotericin B or fluconazole. Treatment duration is individualised based on sensitivity of the organism and patient response (usually ≤7 days, except for cryptococcal meningitis when it is continued for at least 4 mth).

Oral
Systemic fungal infections
Adult: 50-150 mg/kg daily in 4 divided doses. Commonly used w/ amphotericin B or fluconazole in severe infections.
Suy thận
Oral:
Initiate at lower doses. Monitor plasma levels and adjust subsequent doses accordingly to prevent drug accumulation.

Intravenous:
CrCl (mL/min) Dosage
<10 50 mg/kg; further doses should be based on plasma levels (not exceeding 80 mcg/mL).
10-<20 50 mg/kg 24 hrly.
20-40 50 mg/kg 12 hrly.
Cách dùng
May be taken with or without food.
Chống chỉ định
Hypersensitivity to flucytosine. Co-administration w/ antiviral nucleoside drugs and their analogues. Lactation.
Thận trọng
Patient w/ blood dyscrasias or bone marrow depression, dihydropyrimidine dehydrogenase (DPD) deficiency. Patients receiving radiation therapy. Renal and hepatic impairment.
Tác dụng không mong muốn
Nervous: Ataxia, confusion, hallucinations, psychosis, headache, paraesthesia, peripheral neuropathy, parkinsonism, seizures, vertigo, sedation.
CV: Cardiac arrest, myocardial toxicity, ventricular dysfunction, chest pain.
GI: Abdominal pain, dry mouth, bloating, diarrhoea, duodenal ulcer, GI haemorrhage, nausea, vomiting, ulcerative colitis, anorexia.
Resp: Dyspnoea, resp arrest.
Hepatic: Hepatic dysfunction, jaundice, elevated serum alkaline phosphatase, AST, ALT, and bilirubin.
Genitourinary: Increased BUN and serum creatinine, azotaemia, crystalluria, renal failure.
Endocrine: Hypoglycaemia.
Haematologic: Leucopenia, anaemia, pancytopenia, thrombocytopenia, eosinophilia, agranulocytosis.
Otic: Hearing loss.
Dermatologic: Pruritus, rash, urticaria, photosensitivity, toxic epidermal necrolysis.
Others: Fatigue, pyrexia, hypokalaemia, weakness.
Potentially Fatal: Bone marrow toxicity, acute hepatic injury.
Chỉ số theo dõi
Monitor renal, hepatic, and haematologic functions prior to and during treatment (at least wkly in patients w/ renal impairment or blood dyscrasia).
Quá liều
Symptoms: GI effects (e.g. diarrhoea, nausea, vomiting), haematologic effects (e.g. leucopenia, thrombocytopenia), and hepatic effects (e.g. hepatitis). Management: Employ prompt gastric lavage or an emetic. Maintain adequate fluid intake. IV fluids may be given as necessary.
Tương tác
May result in synergistic effect when combined w/ amphotericin B or fluconazole. May increase phenytoin plasma levels. Cytarabine antagonises the antifungal activity of flucytosine by competitive inhibition.
Potentially Fatal: Co-administration w/ antiviral nucleoside drugs (e.g. brivudine, sorivudine, and their analogues) may result in severe drug toxicity due to inhibition of DPD, a key enzyme involved in the metabolism of 5-FU.
Tương tác với thức ăn
Decreased rate of absorption w/ food.
Ảnh hưởng đến kết quả xét nghiệm
May interfere w/ dual-slide enzymatic measurement of creatinine using Ektachem® or Vitros DT 60 analyser; use Jaffe reaction or other alkaline picrate method in determining serum creatinine.
Tác dụng
Description:
Mechanism of Action: Flucytosine is a fluorinated pyrimidine antifungal that is taken up by cytosine permease into the fungal cells. It is rapidly converted to fluorouracil (5-FU) and subsequently into 5-fluorouridine triphosphate (FUTP), which is then incorporated into fungal RNA, resulting to faulty protein biosynthesis. 5-FU is also converted to fluorodeoxyuridine monophosphate which interferes w/ thymidylate synthase, thereby causing disruption of DNA synthesis.
Pharmacokinetics:
Absorption: Absorbed rapidly and almost completely from the GI tract. Bioavailability: 78-89%. Time to peak plasma concentration: W/in 1-2 hr (oral).
Distribution: Widely distributed in body tissues and fluids, including CSF. Crosses the placenta. Volume of distribution: 0.5-1 L/kg.  Plasma protein binding: Approx 2-4%.
Metabolism: Undergoes minimal hepatic metabolism into 5-FU via deamination in yeasts and probably by gut bacteria.
Excretion: Via urine (approx 90%, as unchanged drug). Elimination half-life: 2.5-6 hr.
Đặc tính

Chemical Structure Image
Flucytosine

Source: National Center for Biotechnology Information. PubChem Database. Flucytosine, CID=3366, https://pubchem.ncbi.nlm.nih.gov/compound/Flucytosine (accessed on Jan. 21, 2020)

Bảo quản
Cap: Store between 15-30°C. IV Soln: Store between 18-25°C.
Phân loại MIMS
Thuốc kháng nấm
Phân loại ATC
J02AX01 - flucytosine ; Belongs to the class of other systemic antimycotics.
Tài liệu tham khảo
Ancobon Capsule (Valeant Pharmaceuticals North America LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/03/2017.

Anon. Flucytosine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/03/2017.

Buckingham R (ed). Flucytosine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/03/2017.

Joint Formulary Committee. Flucytosine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/03/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Flucytosine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 07/03/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Flucytosine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in